BeOne Medicines Showcases More Than 60 Abstracts at ASCO and EHA 2026
BeOne Medicines announced that it will present more than 60 scientific abstracts at two of the world’s most influential oncology and hematology conferences in 2026, reinforcing the company’s expanding leadership across blood cancers and solid tumors. The presentations, which will be featured at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2 and the 2026 European Hematology Association Congress in Stockholm from June 11 to June 14, are expected to showcase both the company’s marketed therapies and a broad pipeline of next-generation investigational medicines designed to reshape cancer treatment.
The extensive scientific presence highlights BeOne’s strategy of advancing innovative therapies across multiple oncology settings while building long-term leadership in chronic lymphocytic leukemia (CLL), B-cell malignancies, breast cancer, gastrointestinal tumors, hepatocellular carcinoma, and other high-need cancer indications. The company’s presentations will span oral sessions, rapid oral presentations, and poster discussions, reflecting the depth of its research and development programs.
A major focus of BeOne’s 2026 scientific presentations centers on hematologic malignancies, particularly chronic lymphocytic leukemia. The company plans to unveil new long-term follow-up data supporting the role of BRUKINSA as a foundational treatment option in CLL. The updated findings from the Phase 3 SEQUOIA trial represent one of the longest follow-up periods reported for a BTK inhibitor in frontline CLL treatment and are expected to reinforce the durability and consistency of clinical benefit observed with the therapy.
The SEQUOIA study has become an important component of BeOne’s hematology strategy because it evaluates the long-term efficacy and safety of zanubrutinib in previously untreated CLL patients. According to the company, the latest 78-month follow-up analysis demonstrates continued disease control and sustained outcomes across patient populations, helping establish new expectations for frontline treatment durability in CLL.
The company believes the extended follow-up data are particularly important because they address one of the major concerns in CLL management: maintaining long-term disease suppression while preserving treatment tolerability and flexibility for future sequencing options. The updated findings suggest that patients receiving zanubrutinib continue to derive meaningful clinical benefit over time, supporting the therapy’s growing position within the evolving BTK inhibitor landscape.
Another important presentation at EHA 2026 will involve a subgroup analysis from SEQUOIA focusing on elderly patients aged 80 years and older. This cohort is notable because it represents one of the largest and longest-observed populations of very elderly CLL patients ever evaluated within a Phase 3 clinical trial setting. The analysis is expected to demonstrate that advanced age did not reduce the benefits associated with zanubrutinib therapy, an important consideration given the high prevalence of CLL among older adults.
By highlighting outcomes in elderly patients, BeOne aims to address a significant unmet need in hematologic oncology. Older patients often face limited treatment options due to concerns surrounding toxicity, treatment tolerability, and coexisting medical conditions. Data demonstrating durable efficacy alongside manageable safety in this population could help support broader confidence in treatment decisions for aging CLL patients worldwide.
Amit Agarwal, M.D., Ph.D., Chief Medical Officer for Hematology at BeOne Medicines, emphasized the importance of long-term treatment outcomes in defining leadership within CLL therapy development.
According to Agarwal, the extended SEQUOIA follow-up highlights the critical factors necessary for sustained leadership in CLL treatment, including durable efficacy, confidence in first-line treatment choices, and the ability to support future treatment sequencing strategies. He also pointed to the company’s continued advancement of next-generation therapies, including sonrotoclax-based combinations and the investigational BTK degrader BGB-16673, as central components of BeOne’s long-term hematology vision.
One of the most closely watched investigational programs at EHA 2026 will be BeOne’s BTK degrader candidate, BGB-16673. Updated clinical findings from patients with relapsed or refractory CLL are scheduled for oral presentation and are expected to demonstrate durable anti-tumor activity alongside a manageable safety profile.
The investigational therapy has generated growing interest within the hematology community because BTK degraders represent a next-generation approach that differs mechanistically from traditional BTK inhibitors. Rather than simply blocking BTK signaling, degraders are designed to eliminate the BTK protein itself, potentially overcoming resistance mutations that can emerge with existing therapies.
BeOne noted that more than 1,100 patients have already been dosed with BGB-16673, making it one of the most clinically advanced BTK degrader programs currently in development. In addition to updated relapsed/refractory CLL findings, the company also plans to present previously undisclosed data evaluating the therapy in BTK inhibitor-naïve patients.
The dual presentations underscore the company’s ambition to position BGB-16673 across multiple treatment settings, potentially expanding therapeutic options for patients who either develop resistance to existing BTK inhibitors or require novel frontline strategies.
Another major component of BeOne’s hematology program involves the investigational BCL2 inhibitor sonrotoclax in combination with zanubrutinib. The all-oral combination regimen is designed as a next-generation, time-limited treatment approach for CLL.
Data presented at both ASCO and EHA are expected to demonstrate deep clinical responses, rapid achievement of undetectable measurable residual disease (MRD), and durable remissions in treated patients. The company stated that the combination has also shown a generally favorable tolerability profile, an important consideration in the development of fixed-duration CLL regimens.
The concept of time-limited therapy has become increasingly important within hematologic oncology because it offers the possibility of prolonged disease control without indefinite treatment exposure. BeOne believes the sonrotoclax-zanubrutinib combination may represent a promising future approach capable of balancing efficacy, safety, and long-term treatment convenience.
Beyond hematology, BeOne Medicines is also expected to showcase substantial progress within its solid tumor pipeline at ASCO 2026. The company plans to feature seven distinct therapeutic assets across oral and poster presentations spanning breast cancer, gastrointestinal cancers, gynecologic tumors, and liver cancer.
Central to the company’s solid tumor strategy is TEVIMBRA, its PD-1 inhibitor that continues to expand across multiple oncology indications. BeOne plans to present additional data highlighting the therapy’s differentiated profile in lung and gastrointestinal cancers, including combination strategies with targeted agents.
One particularly important presentation will focus on the HERIZON-GEA-01 clinical trial evaluating TEVIMBRA in combination with ZIIHERA and chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma. The rapid oral presentation will feature a subgroup analysis based on PD-L1 expression status.
According to BeOne, the study demonstrated statistically significant improvements in both overall survival and progression-free survival regardless of PD-L1 expression levels. The findings could support broader applicability of the regimen among HER2-positive gastroesophageal cancer patients. The program is being conducted in partnership with Jazz Pharmaceuticals.
The company also plans to introduce first clinical data for several early-stage investigational therapies that could represent future pillars of its oncology pipeline.
Among these is BGB-43395, a highly selective CDK4 inhibitor being studied in first-line hormone receptor-positive, HER2-negative breast cancer. Phase 1 data are expected to provide initial insights into anti-tumor activity, tolerability, and safety characteristics.
BeOne will additionally present rapid oral findings for BG-C9074, an antibody-drug conjugate targeting B7-H4. The presentation will include dose-escalation and safety expansion data from an ongoing Phase 1 study.
Another investigational therapy drawing attention is BGB-B2033. The molecule is being explored as a potentially first-in-class bispecific antibody designed to target GPC3 and 4-1BB simultaneously in hepatocellular carcinoma. Early clinical findings from heavily pretreated liver cancer patients will be presented during a rapid oral session at ASCO.
Mark Lanasa, M.D., Ph.D., Chief Medical Officer for Solid Tumors at BeOne Medicines, stated that the ASCO presentations reflect the breadth of the company’s scientific capabilities and the speed with which its development programs are advancing.
Lanasa noted that several programs are progressing toward pivotal-stage development simultaneously, positioning the company to potentially establish durable leadership across breast, gynecologic, lung, and gastrointestinal cancers. He emphasized that these are areas where significant unmet medical needs remain for patients globally.
In addition to scientific presentations, the company also announced plans for a major investor webcast on June 1, 2026. The webcast will be led by John V. Oyler, co-founder, chairman, and chief executive officer of BeOne Medicines, alongside other members of the executive leadership team and invited oncology experts.
The presentation is expected to review key scientific and corporate highlights emerging from ASCO 2026 while also providing broader updates on the company’s global research platforms and long-term strategic priorities. Company executives are anticipated to discuss pipeline acceleration efforts, global clinical development capabilities, and the operational infrastructure supporting BeOne’s expanding oncology portfolio.
With more than 60 accepted abstracts spanning both established and emerging therapies, BeOne’s presence at ASCO and EHA 2026 underscores the company’s growing influence within global oncology research. Through long-term CLL data, novel investigational therapies, and expanding solid tumor programs, the company aims to demonstrate not only the maturity of its current portfolio but also the breadth of innovation driving its future pipeline.
As competition intensifies across hematology and solid tumor oncology, the upcoming presentations could play an important role in shaping physician perception, supporting regulatory strategies, and strengthening BeOne’s position within the rapidly evolving global cancer treatment landscape.
About BRUKINSA® (zanubrutinib)
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.
With the broadest label globally, BRUKINSA is the foundational BTK inhibitor. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing and the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.
The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.
About BEQALZI™ (sonrotoclax)
BEQALZI™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. BEQALZI has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.
About BGB-16673
BGB-16673 is a foundational and potential first-in-class and best-in-class Bruton’s tyrosine kinase (BTK) degrader for the treatment of B-cell malignancies. With 1,100+ patients dosed to date in an extensive global clinical development program, BGB-16673 is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025.
Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, BGB-16673 is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.
The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted BGB-16673 PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.
About ZIIHERA (zanidatamab)
ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.1
Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.
ZIIHERA is a registered trademark of Zymeworks BC Inc.
About TEVIMBRA (tislelizumab)
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.
TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.
